SEC calls out lit­tle Ther­a­peu­tic­sMD for its in­sid­er con­tacts with an­a­lysts to boost share price, then halt rout

6 years ago
FDA+

GSK sub­mits its first ap­pli­ca­tion for dapro­du­s­tat in Japan; Two drug­mak­ers part with $15M to avoid opi­oid tri­al

6 years ago
News Briefing

MD­MA, now in Phase III, shows promise as a PTSD treat­ment

6 years ago
R&D

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

6 years ago
R&D

MHRA to land a new in­ter­im chief ex­ec­u­tive ahead of Brex­it

6 years ago
People

[Video] Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha ...

6 years ago
AI

Cowen, Per­cep­tive lead $79.5M Se­ries B for 's­tand­out' biotech shep­herd­ing on­colyt­ic virus to clin­ic

6 years ago
Financing

Fu­til­i­ty analy­sis au­gurs de­feat in piv­otal tri­al test­ing of Nu­Cana's lead drug in metasta­t­ic pan­cre­at­ic can­cer

6 years ago
R&D

As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

6 years ago
R&D
Pharma

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

6 years ago
FDA+

Pfiz­er Foun­da­tion of­fers $2M in grants to NGOs tack­ling an­timi­cro­bial re­sis­tance; Bio­gen, In­vi­tae join forces to ...

6 years ago
News Briefing

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

6 years ago
R&D
FDA+

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

6 years ago
R&D

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

6 years ago
Deals
Pharma

Fresh from $102M haul, IGM Bio pitch­es $100M IPO as it plots first-in-hu­man tri­al of new an­ti­bod­ies

6 years ago
Financing

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

6 years ago
R&D
Pharma

Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

6 years ago
R&D
FDA+

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

6 years ago
People

No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

6 years ago
R&D
Pharma

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

6 years ago
People

Glen­mark launch­es Re­mogliflozin com­bo in In­dia; Gene­Cen­tric Ther­a­peu­tics buys Se­lect Im­munoGenomics

6 years ago
News Briefing

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA ...

6 years ago
R&D

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

6 years ago
Financing

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

6 years ago
R&D
First page Previous page 906907908909910911912 Next page Last page
A service from the Financial Times